Ohara Pharmaceutical

Ohara Pharmaceuticals is a pharmaceutical company engaged in the development, manufacture, and distribution of a variety of pharmaceutical products. The company focuses on delivering high-quality medications to meet the needs of healthcare providers and patients. Through its comprehensive approach, Ohara Pharmaceuticals aims to contribute to the advancement of medical treatment options and improve patient outcomes.

Seiji Ohara

President and CEO

12 past transactions

Mydawa

Venture Round in 2025
Mydawa operates an online pharmacy platform that connects patients directly with drug stores. It offers a wide range of high-quality medicines and wellness products, enabling consumers to purchase these affordably and conveniently via their mobile phones.

Africa Healthcare Network

Debt Financing in 2023
Africa Healthcare Network (AHN) is a pioneering provider of dialysis services in Sub-Saharan Africa, establishing the first chain of dialysis centers in the region. The organization focuses on delivering high-quality, life-saving dialysis treatment at affordable prices, addressing the critical shortage of accessible care for patients suffering from Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). With a commitment to improving healthcare in a region faced with limited resources and a rising prevalence of Chronic Kidney Disease (CKD) due to urbanization and lifestyle diseases, AHN combines global technical expertise with practical operational experience. The organization aims to enhance the quality of care while reducing costs for patients by securing high-quality equipment, training healthcare professionals, and optimizing operational efficiency. Operating in Rwanda, Tanzania, and Kenya, AHN seeks to increase patient access to essential dialysis services, fostering better health outcomes and providing a sustainable business model.

Africa Healthcare Network

Venture Round in 2023
Africa Healthcare Network (AHN) is a pioneering provider of dialysis services in Sub-Saharan Africa, establishing the first chain of dialysis centers in the region. The organization focuses on delivering high-quality, life-saving dialysis treatment at affordable prices, addressing the critical shortage of accessible care for patients suffering from Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). With a commitment to improving healthcare in a region faced with limited resources and a rising prevalence of Chronic Kidney Disease (CKD) due to urbanization and lifestyle diseases, AHN combines global technical expertise with practical operational experience. The organization aims to enhance the quality of care while reducing costs for patients by securing high-quality equipment, training healthcare professionals, and optimizing operational efficiency. Operating in Rwanda, Tanzania, and Kenya, AHN seeks to increase patient access to essential dialysis services, fostering better health outcomes and providing a sustainable business model.

Helium Health

Series B in 2023
Helium Health specializes in digitizing healthcare systems in Africa. It offers software tools for hospitals and clinics to manage patient health records, operations, and telemedicine. The company aims to create the largest healthcare data exchange in Africa.

Revital Healthcare

Venture Round in 2021
Revital Healthcare is a manufacturer based in Kilifi, Kenya, specializing in medical devices and disposables for hospitals and medical laboratories. Established in 2006, the company produces a range of products, including single-use syringes, needles, re-use prevention syringes, and auto-disable syringes, all designed to minimize the transmission of HIV and other blood-borne diseases. In addition to these syringes, Revital Healthcare offers infusion sets, blood transfusion sets, and blood collection tubes, ensuring that healthcare providers have access to quality and affordable medical supplies.

HACARUS

Series B in 2020
Hacarus Inc. is a technology company based in Kyoto, Japan, that specializes in artificial intelligence solutions for the manufacturing and medical sectors. Established in 2014, Hacarus develops products that leverage its proprietary Sparse Modeling technology, which allows for efficient data analysis and decision-making. The company offers several key platforms, including SALUS, which caters to medical and life sciences applications, and COLIGO, a customizable application that supports various implementations in IoT and edge computing. Additionally, Hacarus provides SPECTRO, a tool for enhanced visual inspections, and offers data science consulting services along with an AI Academy for education in AI technologies. By focusing on small data and resource-efficient solutions, Hacarus aims to deliver insights that enable faster and more reliable decision-making compared to traditional deep learning approaches.

J-Pharma

Series D in 2020
J-Pharma specializes in developing novel pharmaceuticals based on a human-genomic approach. Its intellectual property focuses on cell membrane transporters linked to various diseases, enabling the creation of targeted drugs and diagnostic methods. The company aims to improve global health and enhance quality of life for aging populations by generating new drug agents.

Helium Health

Series A in 2020
Helium Health specializes in digitizing healthcare systems in Africa. It offers software tools for hospitals and clinics to manage patient health records, operations, and telemedicine. The company aims to create the largest healthcare data exchange in Africa.

Prism BioLab

Venture Round in 2019
Prism BioLab is focused on drug discovery and development, utilizing its proprietary PepMetics Technology to create therapeutic agents. The company specializes in treatments for non-oncology indications, particularly targeting conditions such as pulmonary fibrosis and other incurable diseases. By leveraging its innovative platform, Prism BioLab aims to provide effective solutions for these challenging health issues.

HekaBio

Series A in 2018
HekaBio is a healthcare platform that invests in and develops innovative oncology, radiation therapy, and cardiovascular treatments. It offers expertise across pharma, medical devices, diagnostics, digital health, and cell therapies to accelerate patient access to global healthcare innovations.

HACARUS

Series A in 2018
Hacarus Inc. is a technology company based in Kyoto, Japan, that specializes in artificial intelligence solutions for the manufacturing and medical sectors. Established in 2014, Hacarus develops products that leverage its proprietary Sparse Modeling technology, which allows for efficient data analysis and decision-making. The company offers several key platforms, including SALUS, which caters to medical and life sciences applications, and COLIGO, a customizable application that supports various implementations in IoT and edge computing. Additionally, Hacarus provides SPECTRO, a tool for enhanced visual inspections, and offers data science consulting services along with an AI Academy for education in AI technologies. By focusing on small data and resource-efficient solutions, Hacarus aims to deliver insights that enable faster and more reliable decision-making compared to traditional deep learning approaches.

Jiksak Bioengineering

Venture Round in 2018
Jiksak Bioengineering, Inc. is a biotechnology company specializing in the development of microfluidic devices and screening technologies aimed at addressing neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease. Founded in 2017 and headquartered in Kawasaki, Japan, the company utilizes innovative three-dimensional cell tissue models known as "Nerve Organoids" to enhance drug screening processes. By creating nerve tissue products that mimic human physiology, Jiksak Bioengineering aims to facilitate the identification of effective treatments for these debilitating conditions, ultimately enabling healthcare professionals to improve patient outcomes in the field of neurodegeneration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.